In a recent survey of major pharma companies, most anticipated a shift to flow of up to 25% of the total portfolio in the next 15 years.1 Moreover, the US FDA has released guidance promoting continuous manufacturing processes with the aim of improving product quality, which is the main underlying cause of drug shortages and recalls.2 Flow offers a number of important advantages over batch in terms of the quality, safety, agility, sustainability and speed of the overall process.